Nurix Therapeutics (NRIX) Projected to Post Earnings on Thursday

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, July 10th. Analysts expect Nurix Therapeutics to post earnings of ($0.73) per share and revenue of $16.26 million for the quarter.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. During the same period in the previous year, the business posted ($0.76) earnings per share. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $12.44 on Thursday. The business's 50 day simple moving average is $11.07 and its 200 day simple moving average is $14.21. Nurix Therapeutics has a 1 year low of $8.18 and a 1 year high of $29.56. The company has a market capitalization of $948.43 million, a P/E ratio of -4.44 and a beta of 2.15.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the sale, the insider directly owned 61,516 shares in the company, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer directly owned 33,724 shares in the company, valued at approximately $382,092.92. The trade was a 15.53% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,013 shares of company stock valued at $137,096. Corporate insiders own 7.40% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Nurix Therapeutics by 11.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company's stock valued at $593,000 after purchasing an additional 5,286 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Nurix Therapeutics by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company's stock valued at $1,895,000 after acquiring an additional 12,817 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company's stock valued at $6,029,000 after acquiring an additional 44,002 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in Nurix Therapeutics by 106.2% in the first quarter. Millennium Management LLC now owns 874,399 shares of the company's stock worth $10,388,000 after acquiring an additional 450,262 shares during the period.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. Needham & Company LLC reiterated a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Wells Fargo & Company lowered their price target on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. Leerink Partners began coverage on Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Nurix Therapeutics has an average rating of "Moderate Buy" and an average price target of $30.18.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.